Patents by Inventor Sherie L. Morrison

Sherie L. Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
    Patent number: 10975158
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 13, 2021
    Assignee: The Regents of the University of California
    Inventor: Sherie L. Morrison
  • Anti-CSPG4 fusions with interferon for the treatment of malignancy
    Patent number: 10822427
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a nutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: November 3, 2020
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • ANTI-CSPG4 FUSIONS WITH INTERFERON FOR THE TREATMENT OF MALIGNANCY
    Publication number: 20190135939
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a nutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Application
    Filed: October 2, 2018
    Publication date: May 9, 2019
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • Targeted interferons demonstrate potent apoptotic and anti-tumor activities
    Patent number: 10182984
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 22, 2019
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • Anti-CSPG4 fusions with interferon for the treatment of malignancy
    Patent number: 10093745
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a mutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 9, 2018
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • CD138-TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES
    Publication number: 20180162948
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha.
    Type: Application
    Filed: October 20, 2017
    Publication date: June 14, 2018
    Inventor: Sherie L. Morrison
  • CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
    Patent number: 9803021
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: October 31, 2017
    Assignee: The Regents of the University of California
    Inventor: Sherie L. Morrison
  • TARGETED INTERFERONS DEMONSTRATE POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES
    Publication number: 20170151342
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Application
    Filed: November 22, 2016
    Publication date: June 1, 2017
    Inventors: SHERIE L. MORRISON, TZU-HSUAN HUANG, CAIYUN XUAN
  • Antibody-endostatin fusion protein and its variants
    Patent number: 9611313
    Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 4, 2017
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Seung-Uon Shin, Joseph David Rosenblatt, Sherie L. Morrison
  • Targeted interferons demonstrating potent apoptotic and anti-tumor activities
    Patent number: 9534033
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: January 3, 2017
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • ANTI-CSPG4 FUSIONS WITH INTERFERON FOR THE TREATMENT OF MALIGNANCY
    Publication number: 20160115242
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a mutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Application
    Filed: May 29, 2014
    Publication date: April 28, 2016
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • CD138-TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES
    Publication number: 20160115239
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha.
    Type: Application
    Filed: December 5, 2013
    Publication date: April 28, 2016
    Inventor: Sherie L. Morrison
  • Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
    Patent number: 9139634
    Abstract: This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: September 22, 2015
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS
    Publication number: 20140220016
    Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 7, 2014
    Applicant: University of Miami
    Inventors: Seung-Uon Shin, Joseph David Rosenblatt, Sherie L. Morrison
  • TARGETED INTERFERONS DEMONSTRATE POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES
    Publication number: 20140079668
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Application
    Filed: August 30, 2013
    Publication date: March 20, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: SHERIE L. MORRISON, TZU-HSUAN HUANG, CAIYUN XUAN
  • Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
    Patent number: 8563692
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: October 22, 2013
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
    Patent number: 8258263
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: September 4, 2012
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
  • METHOD FOR TARGETED AND SUSTAINED ANTIVIRAL THERAPY
    Publication number: 20110165122
    Abstract: Compounds compositions and methods of modulating the immune response are provided. The method uses fusion proteins of a cytokine and an antibody to potentiate the action of the cytokine.
    Type: Application
    Filed: November 10, 2010
    Publication date: July 7, 2011
    Applicant: The Regents of the University of California
    Inventors: Arash Shahangian, Genhong Cheng, Lucy S. Cheng, Kham Moc Trinh, Paul W. Dempsey, Beichu Guo, Sherie L. Morrison
  • TARGETED INTERFERONS DEMONSTRATE POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES
    Publication number: 20110104112
    Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).
    Type: Application
    Filed: January 5, 2011
    Publication date: May 5, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: SHERIE L. MORRISON, TZU-HSUAN HUANG, CAIYUN XUAN
  • ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS
    Publication number: 20110038865
    Abstract: Chimeric molecules comprising endostatin and all or a portion of a tumor antigen specific binding molecule for use in treating tumors. The chimeric molecule, includes endostatin, endostatin mutants and variants and an antibody or aptamer specific for a desired tumor antigen. Methods of treating cancer comprise administering the chimeric fusion molecules.
    Type: Application
    Filed: June 26, 2008
    Publication date: February 17, 2011
    Applicant: University of Miami
    Inventors: Seung-Uon Shin, Joseph David Rosenblatt, Sherie L. Morrison